Oruka Therapeutics’ (ORKA) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Oruka Therapeutics (NASDAQ:ORKA) in a research note published on Thursday morning, Benzinga reports. They currently have a $45.00 price target on the stock.

ORKA has been the subject of a number of other reports. Lifesci Capital assumed coverage on shares of Oruka Therapeutics in a report on Monday, September 16th. They set an “outperform” rating and a $41.00 target price for the company. Leerink Partnrs upgraded Oruka Therapeutics to a “strong-buy” rating in a report on Tuesday, September 17th. Stifel Nicolaus assumed coverage on Oruka Therapeutics in a research report on Friday, October 11th. They set a “buy” rating and a $49.00 target price on the stock. Wedbush began coverage on Oruka Therapeutics in a research report on Wednesday, September 4th. They issued an “outperform” rating and a $40.00 price target for the company. Finally, Jefferies Financial Group assumed coverage on Oruka Therapeutics in a report on Friday, September 13th. They set a “buy” rating and a $40.00 price objective on the stock. Six analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and an average target price of $43.17.

Oruka Therapeutics Price Performance

Shares of ORKA stock opened at $27.19 on Thursday. The company’s 50-day moving average price is $26.86. The company has a market capitalization of $32.90 million, a PE ratio of -4.53 and a beta of 0.87. Oruka Therapeutics has a fifty-two week low of $18.72 and a fifty-two week high of $53.88.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($25.92) earnings per share (EPS) for the quarter. Sell-side analysts expect that Oruka Therapeutics will post -1.69 EPS for the current year.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.